Exhibit 5.1

| | |
4 March 2021 | | Our Ref: JT/MK/A6231-S11774 |
ASLAN Pharmaceuticals Limited
Walkers Corporate Limited
190 Elgin Avenue
George Town
Grand Cayman KY1-9008
Cayman Islands
Dear Sirs
ASLAN Pharmaceuticals Limited
We have acted as Cayman Islands legal advisers to ASLAN Pharmaceuticals Limited (the “Company”) in connection with the offering by the Company of up to 17,250,000 American Depositary Shares (the “ADSs”) representing 86,250,000 ordinary shares of the Company of a par value of US$0.01 each (the “Ordinary Shares” and, together with the ADSs, the “Securities”), including up to 2,250,000 ADSs that may be sold pursuant to the exercise of an option to purchase additional ADSs, pursuant to the Company’s registration statement on Form F-3 (Registration No. 333-252575), including all amendments or supplements thereto (the “Registration Statement”), filed on 29 January 2021 with the Securities and Exchange Commission under the U.S. Securities Act of 1933, as amended (the “Securities Act”), the prospectus included in the Registration Statement (the “Base Prospectus”), and the prospectus supplement dated 2 March 2021 relating to the Securities (together with the Base Prospectus, the “Prospectus”). We are furnishing this opinion as exhibit 5.1 to the Company’s Report on Form 6-K filed with the Securities and Exchange Commission on 4 March 2021.
For the purposes of giving this opinion, we have examined and relied upon the originals, copies or translations of the documents listed in Schedule 1.
In giving this opinion we have relied upon the assumptions set out in Schedule 2, which we have not independently verified.
We are Cayman Islands Attorneys at Law and express no opinion as to any laws other than the laws of the Cayman Islands in force and as interpreted at the date of this opinion. We have not, for the purposes of this opinion, made any investigation of the laws, rules or regulations of any other jurisdiction. Except as explicitly stated herein, we express no opinion in relation to any representation or warranty contained in any of the documents cited in this opinion nor upon matters of fact or the commercial terms of the transactions the subject of this opinion.
Based upon the examinations and assumptions stated herein and upon such searches as we have conducted and having regard to legal considerations which we consider relevant, and subject to the qualifications set out in Schedule 3, and under the laws of the Cayman Islands, we give the following opinions in relation to the matters set out below.
Walkers (Singapore) Limited Liability Partnership
UEN/Reg. No. T09LL0833E
3 Church Street, 16-02 Samsung Hub, Singapore 049483
T +65 6595 4670 F +65 6595 4671 www.walkersglobal.com
Bermuda | British Virgin Islands | Cayman Islands | Dubai | Dublin | Guernsey | Hong Kong | Jersey | London | Singapore